Multicenter Phase II Trial Of Paclitaxel (P), Ifosfamide (I), And Carboplatin (C) In Previously Untreated Extensive Stage Small Cell Lung Cancer (ES?SCLC)
Reviewer: Roberto Santiago, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: May 19, 2002
Presenter: Marcus A Neubauer
Presenter's Affiliation: US Oncology Inc, Houston, TX
Type of Session: Poster
- ES-SCLC accounts for 60-70% of the 30-35,000 new cases of SCLC diagnosed each year in the US
- The median survival for ES-SCLC reported in phase III trials is 9-12 months
- Overall survival at 2 years is < 10% and little progress in survival outcomes has been made over the last decade
- Platinum + etoposide are considered the standard of care but P, I, and C have been shown to be active as single agents as well as when parts of combination regimens.
- A recent phase III trial showed improved survival in ES-SCLC patients treated with cisplatin and irinotecan
- This phase II trial evaluates the activity and toxicity profile of a combination of P (175mg/m2/h), I (2.5 gm/m2/h with mesna), and C (AUC=6 over 0.5h) all given on day 1 and repeated every 21 days for 6 cycles
- The regimen used was previously evaluated in patients with ES-SCLC refractory to platinum + etoposide (RR, 73%; median survival, 28 weeks; 1-year OS, 12%)
Materials and Methods
- 22 men and 13 women with clinically assessable, histologically confirmed ES-SCLC were enrolled
- No previous chemotherapy was allowed; last radiotherapy a least 2 weeks prior to this regimen
- Patients had an ECOG performing status between 0 and 2 (0-1, 86%) and a median age of 59 years (range 40?79)
- Patients with previous malignancy, serious co-morbidities, or end-organ dysfunction were not eligible
- A median of 6 cycles (range 1?6) were delivered per patient for a total of 193 cycles
- Grade 3 toxicity was observed in the following percent of patients: Neutropenia, 14%; anemia, 17%; platelets, 17%; neuropathy, 3%; nausea, 0%; CNS, 3%; HSR, 0%
- Grade 4 toxicity was observed in the following percent of patients: Neutropenia, 66%; anemia, 0%; platelets, 3%; neuropathy, 0%; nausea, 0%; CNS, 0%; HSR, 3%
- Grade 2 alopecia and myalgia/arthralgia were observed in 46% and 14% of the patients, respectively
- Neutropenic fever was developed by 9% of the patients
- 1 treatment-related death occurred in a patient that had febrile neutropenia
- The overall, complete, and partial response rates were 69%, 14% and 55%, respectively (23% are not assessable as of yet)
- Median survival was 9.5 months, 1-year survival was 42% and 2-year survival was 12%
- PIC is an active and well tolerated regimen in ES-SCLC
- Response rates and overall survival are similar to other regimens commonly used in ES-SCLC
- Neutropenia was the principal toxicity of this regimen
- The regimen proved convenient for outpatient delivery since it was feasible to administer in a single half-day
Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
Gefitinib Outperforms Combo Therapy in Lung Cancer Trial
Feb 26, 2015 - In a phase III clinical trial, gefitinib was superior to carboplatin-paclitaxel in extending survival for patients with non-small-cell lung cancer, particularly those patients with epidermal growth factor receptor gene mutations, according to a study published online Aug. 19 in the New England Journal of Medicine.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!